Teacher Retirement System of Texas’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $168K | Buy |
40,504
+894
| +2% | +$3.4K | ﹤0.01% | 1477 |
|
|
2026
Q1 | $139K | Sell |
39,610
-5,437
| -12% | -$17.4K | ﹤0.01% | 1441 |
|
|
2025
Q4 | $123K | Sell |
45,047
-19,739
| -30% | -$45.7K | ﹤0.01% | 1581 |
|
|
2025
Q3 | $141K | Sell |
64,786
-5,592
| -8% | -$13.2K | ﹤0.01% | 1951 |
|
|
2025
Q2 | $121K | Buy |
70,378
+12,963
| +23% | +$32.3K | ﹤0.01% | 1982 |
|
|
2025
Q1 | $191K | Sell |
57,415
-5,610
| -9% | -$28.9K | ﹤0.01% | 1894 |
|
|
2024
Q4 | $466K | Buy |
63,025
+13,895
| +28% | +$129K | ﹤0.01% | 1279 |
|
|
2024
Q3 | $461K | Buy |
49,130
+6,202
| +14% | +$58.8K | ﹤0.01% | 1224 |
|
|
2024
Q2 | $344K | Buy |
42,928
+208
| +0.5% | +$2.23K | ﹤0.01% | 1319 |
|
|
2024
Q1 | $633K | Sell |
42,720
-8,878
| -17% | -$103K | ﹤0.01% | 1186 |
|
|
2023
Q4 | $419K | Sell |
51,598
-11,691
| -18% | -$61.2K | ﹤0.01% | 1447 |
|
|
2023
Q3 | $288K | Buy |
63,289
+11,995
| +23% | +$78.3K | ﹤0.01% | 1613 |
|
|
2023
Q2 | $361K | Buy |
51,294
+14,826
| +41% | +$106K | ﹤0.01% | 1558 |
|
|
2023
Q1 | $223K | Buy |
36,468
+746
| +2% | +$5.15K | ﹤0.01% | 1839 |
|
|
2022
Q4 | $228K | Sell |
35,722
-2,840
| -7% | -$22.2K | ﹤0.01% | 1797 |
|
|
2022
Q3 | $369K | Buy |
38,562
+18,531
| +93% | +$214K | ﹤0.01% | 1663 |
|
|
2022
Q2 | $221K | Sell |
20,031
-5,778
| -22% | -$75.7K | ﹤0.01% | 1629 |
|
|
2022
Q1 | $430K | Buy |
25,809
+2,182
| +9% | +$33.7K | ﹤0.01% | 1485 |
|
|
2021
Q4 | $451K | Buy |
23,627
+4,681
| +25% | +$103K | ﹤0.01% | 1542 |
|
|
2021
Q3 | $467K | Buy |
18,946
+4,735
| +33% | +$112K | ﹤0.01% | 1395 |
|
|
2021
Q2 | $370K | Buy |
14,211
+2,155
| +18% | +$56K | ﹤0.01% | 1446 |
|
|
2021
Q1 | $382K | Buy |
12,056
+2,258
| +23% | +$93.6K | ﹤0.01% | 1276 |
|
|
2020
Q4 | $455K | Buy |
9,798
+3,688
| +60% | +$146K | ﹤0.01% | 974 |
|
|
2020
Q3 | $201K | Buy |
+6,110
| New | +$187K | ﹤0.01% | 1079 |
|
|
2018
Q3 | – | Sell |
-14,464
| Closed | -$185K | – | 1660 |
|
|
2018
Q2 | $185K | Sell |
14,464
-623
| -4% | -$9.11K | ﹤0.01% | 1801 |
|
|
2018
Q1 | $255K | Sell |
15,087
-4,218
| -22% | -$63.9K | ﹤0.01% | 1629 |
|
|
2017
Q4 | $154K | Buy |
+19,305
| New | +$155K | ﹤0.01% | 2144 |
|
|
2016
Q3 | – | Sell |
-6,003
| Closed | -$49K | – | 1699 |
|
|
2016
Q2 | $49K | Buy |
6,003
+729
| +14% | +$4.58K | ﹤0.01% | 2238 |
|
|
2016
Q1 | $27K | Buy |
5,274
+1,355
| +35% | +$7.42K | ﹤0.01% | 2425 |
|
|
2015
Q4 | $30K | Sell |
3,919
-504
| -11% | -$3.5K | ﹤0.01% | 2334 |
|
|
2015
Q3 | $25K | Buy |
4,423
+3,012
| +213% | +$23.5K | ﹤0.01% | 2412 |
|
|
2015
Q2 | $13K | Buy |
+1,411
| New | +$15.7K | ﹤0.01% | 2318 |
|
Other funds holding IOVA
MFM
PAI
Teacher Retirement System of Texas's IOVA Position: Q2 2026 in Review
Teacher Retirement System of Texas increased its Iovance Biotherapeutics (IOVA) stake by 2.3% in Q2 2026, buying an estimated $3.4K and bringing the position to 40,504 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #1477.
Teacher Retirement System of Texas first reported a position in IOVA in Q2 2015 and has held it in 32 quarters since. The position peaked at $633K in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.
- Teacher Retirement System of Texas held 40,504 shares of Iovance Biotherapeutics worth $168K as of Q2 2026.
- Teacher Retirement System of Texas bought 894 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.4K.
- Iovance Biotherapeutics made up ﹤0.01% of Teacher Retirement System of Texas's portfolio in Q2 2026, its #1477 holding.
- Teacher Retirement System of Texas first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 32 quarters since.
- Teacher Retirement System of Texas's Iovance Biotherapeutics position peaked at $633K in Q1 2024.
- 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.
Based on Teacher Retirement System of Texas's 13F filing for Q2 2026, filed 14 Aug 2026.